CVS Health Corporation provides health services in the United States.
$83.85+3.10%
报价 2026-11-06
市值
$107.24B
EV
$175.78B
PE (TTM)
51.2x
预期 PE (FY2026)
10.4x
52 周区间距高点 -24.2%
$70.08$110.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.0x | 8.33 → 8.53（1.0x） | 9.8 |
| FY+32028-12 | 1.1x | 8.33 → 9.70（1.2x） | 8.6 |
毛利率 14% · TTM 收入 $420614M · 基数 EPS 8.33（调整后）
电话会信号
辅助标签Q3 20262026-11-04
上调指引盈利拐点
指引 上调
信心 5
分析师 3
“We now expect to deliver at least $8.65 in adjusted EPS in 2027, reflecting approximately 13% growth off an adjusted 2026 baseline.”
原文引用（2）
- 上调指引：we are raising our full-year 2026 adjusted earnings per share guidance to at least $8.20, an increase from our prior range of $7.90 to $8.10
- 盈利拐点：We are moving into the profitable territory in 2026, so I can confirm that.
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| CVSCVS Health Corporation | $107.24B | +3.1% | +1.7% | 13.8% | 51.2x | 17.8x | 13.7x | |
| VRTXVertex Pharmaceuticals Incorporated | $138.67B | +0.8% | +8.8% | 86.3% | 29.0x | 23.5x | 43.4x | |
| MDTMedtronic plc | $130.22B | -2.9% | +8.0% | 62% | 24.2x | 14.8x | – | |
| BMYBristol-Myers Squibb Company PFD CONV 2 | $127.02B | -1.6% | -1.5% | 67.7% | 16.5x | 10.5x | 9.9x | |
| MCKMcKesson Corporation | $123.68B | -1.0% | +6.6% | 3.6% | 24.9x | 17.6x | 12.2x | |
| HCAHCA Healthcare, Inc. | $103.4B | -2.5% | +4.5% | 14.9% | 16.4x | 9.7x | 17.3x | |
| GSKGSK plc | $102.02B | -0.2% | – | 72.5% | 13.7x | 7.8x | – | |
| ELVElevance Health Inc. | $91.96B | -1.5% | -1.9% | 25.6% | 11.3x | 9.1x | 29.2x | |
| CICigna Corporation | $77.58B | -2.6% | +4.5% | 9.5% | 11.7x | 7.8x | 9.2x | Cheap |
| 同行中位数 | – | – | +4.5% | 43.8% | 16.4x | 10.1x | 14.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。